Table 2—

Incidence rates of CHD events in patients with or without the metabolic syndrome on simvastatin or placebo

End point event and groupn/N (%)
Event rates/100 patient-years
Difference from placebo95% CI for difference
SIMVAPBOSIMVAPBO
Total mortality
 MetS present35/423 (8.3)66/470 (14.0)1.572.77−1.20−2.04 to −0.35
 MetS absent111/1,532 (7.3)149/1,508 (9.9)1.371.89−0.52−0.91 to −0.12
Coronary mortality
 MetS present20/423 (4.7)53/470 (11.3)0.902.22−1.32−2.04 to −0.61
 MetS absent68/1,532 (4.4)106/1,508 (7.0)0.841.34−0.50−0.83 to −0.18
Major coronary event
 MetS present87/423 (20.6)150/470 (31.9)4.357.32−2.97−4.45 to −1.48
 MetS absent282/1,532 (18.4)380/1,508 (25.2)3.805.38−1.58−2.28 to −0.88
Revascularization
 MetS present48/423 (11.4)87/470 (18.5)2.294.07−1.78−2.85 to −0.71
 MetS absent174/1,532 (11.4)246/1,508 (16.3)2.293.38−1.09−1.63 to −0.55
Any CHD event
 MetS present137/423 (32.4)202/470 (43.0)7.5710.89−3.32−5.28 to −1.35
 MetS absent481/1,532 (31.4)602/1,508 (39.9)7.139.45−2.32−3.31 to −1.34
Stroke
 MetS present11/423 (2.6)19/470 (4.0)0.500.81−0.31−0.78 to 0.16
 MetS absent48/1,532 (3.1)65/1,508 (4.3)0.600.84−0.24−0.50 to 0.03
Any atherosclerotic event
 MetS present152/423 (35.9)223/470 (47.5)8.4612.28−3.82−5.92 to −1.72
 MetS absent536/1,532 (35.0)666/1,508 (44.2)8.0410.62−2.58−3.63 to −1.52
  • MetS, metabolic syndrome; PBO, placebo; SIMVA, simvastatin.